Biblio Discovery — Demo Discovery Service

7 results for "James E. Ferguson"

Showing 1–7 · 2.33 seconds · RSS

  1. Journal Article Full text

    The ubiquitin ligase ASB4 promotes trophoblast differentiation through the degradation of ID2.

    W H Davin Townley-Tilson; Yaxu Wu; James E Ferguson et al.

    PLoS ONE, Vol. 9 No. 2 · 2014 · English · DOAJ Scopus

    Vascularization of the placenta is a critical developmental process that ensures fetal viability. Although the vascular health of the placenta affects both maternal and fetal well being, relatively little is known about the early stages of placental vascular development. The ubiquitin ligase…

    Also available at: PLOS

  2. Journal Article

    EZH2-Targeted Therapies in Cancer: Hype or a Reality

    Marie‐Lisa Eich; Mohammad S. Athar; James E. Ferguson et al.

    Cancer Research · 2020 · English · OpenAlex Scopus

    Abstract Next-generation genomic sequencing has identified multiple novel molecular alterations in cancer. Since the identification of DNA methylation and histone modification, it has become evident that genes encoding epigenetic modifiers that locally and globally regulate gene expression play a…

  3. Journal Article

    Expression and Role of Methylenetetrahydrofolate Dehydrogenase 1 Like (MTHFD1L) in Bladder Cancer

    Marie-Lisa Eich; Maria Del Carmen Rodriguez Pena; Darshan Shimoga Chandrashekar et al.

    Translational Oncology, Vol. 12 No. 11 · 2019 · English · DOAJ Scopus

    Cancer cells utilize vitamin folate to fulfill their excessive demand for nucleotides and amino acids. Dihydrofolate reductase (DHFR), an enzyme involved in folate metabolism converts dihydrofolate into tetrahydrofolate, which is required for the de novo synthesis of purines, and certain amino…

  4. Journal Article

    Inhibition of urothelial carcinoma through targeted type I interferon-mediated immune activation

    Devin Plote; Woonyoung Choi; Sharada Mokkapati et al.

    OncoImmunology, Vol. 8 No. 5 · 2019 · English · DOAJ Scopus

    Type I interferon (IFN-I) has potent anti-tumor effects against urothelial carcinoma (UC) and may be an alternative treatment option for patients who do not respond to Bacillus Calmette-Guerin. However, the mechanisms that mediate the IFN-I-stimulated immune responses against UC have yet to be…

  5. Journal Article

    Neoadjuvant pazopanib and molecular analysis of tissue response in renal cell carcinoma

    Christopher G. Wood; James E. Ferguson III; Joel S. Parker et al.

    JCI Insight, Vol. 5 No. 22 · 2020 · English · DOAJ Scopus

    BACKGROUND Surgery remains the frontline therapy for patients with localized clear cell renal cell carcinoma (ccRCC); however, 20%–40% recur. Angiogenesis inhibitors have improved survival in metastatic patients and may result in responses in the neoadjuvant setting. The impact of these agents on…

  6. Journal Article

    ARID1A-deficient bladder cancer is dependent on PI3K signaling and sensitive to EZH2 and PI3K inhibitors

    Hasibur Rehman; Darshan S. Chandrashekar; Chakravarthi Balabhadrapatruni et al.

    JCI Insight, Vol. 7 No. 16 · 2022 · English · DOAJ Scopus

    Metastatic urothelial carcinoma is generally incurable with current systemic therapies. Chromatin modifiers are frequently mutated in bladder cancer, with ARID1A-inactivating mutations present in about 20% of tumors. EZH2, a histone methyltransferase, acts as an oncogene that functionally opposes…